MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
US10894837B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 15, 2017 |
| Grant date | Jan 19, 2021 |
| Priority date | — |
| Expiry date | Dec 15, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/24035
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the field of therapy, in particular dermatology. Inventors herein identify for the first time inhibitors of matrix metalloproteinase-9 (MMP9) as active molecules for use for preventing, treating or alleviating skin depigmenting disorders in a subject in need thereof, and describe compositions and kits comprising such inhibitors as well as uses thereof. Inventors further describe a method for screening pharmaceutically active molecules suitable for preventing, treating or alleviating a depigmenting disorder as well as methods for evaluating the efficacy of a depigmenting disorder treatment involving an inhibitor of MMP9 or for monitoring the course of depigmenting disorder in a subject exposed to such a treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.